Spring 2015 Clinical Vaccinology Course
18th Annual Conference on Vaccine Research
The 51st Semi-Annual Denver TB Course
AMMI Canada - CACMID Annual Conference
Find Practice Guidelines
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
Better Tests, Better Care: The Promise of Next Generation Diagnostics
This report for policymakers highlights the need for new diagnostics and recommends policies to stimulate diagnostics R&D and clinical integration.
IDSA Provides Testimony in Support of Supplemental Funding for Ebola Preparedness and Response Efforts
IDSA voiced support for the President’s emergency funding request to Congress to address Ebola and has also volunteered to lend its expertise and resources to aid in the U.S. and global response to the outbreak in a communication to Ebola Czar, Ron Klain.
IDSA, PIDS, and HIVMA Comments on NIH Physician-Scientist Workforce Report
IDSA, along with PIDS and HIVMA, jointly commented on the NIH Physician-Scientist Workforce Working Group report highlighting recommendations to improve the state of the physician-scientist workforce.
IDSA President Provides Testimony on the Need for New Antibiotics
On September 19th,
IDSA President Barbara Murray provided testimony to the Health Subcommittee of
the House Energy & Commerce Committee on the need for a coordinated federal
strategy to spur research and development for new antibiotics.
Tell Congress #CutsHurt!
Your help is needed to send a strong message to Congress that federal agency and program funding levels need to be finalized in the weeks ahead, so that new cuts are not set into motion.
Take Three Minutes to Support Antibiotic Development
Urge Congress to help speed patient access to the most urgently needed new antibacterial drugs.
IDSA Members Call on Congress to Advance LPAD Pathway
IDSA members answered a request from the House Energy and Commerce Committee on proposals to spur drug research and development.
The STAAR Act was reintroduced by Sen. Sherrod Brown this week. The bill, championed by IDSA, provides stronger federal leadership to coordinate activities that address resistance and strengthen accountability.
1 of 8
Approval changes to the Kaletra label
U.S. Multi-state Measles Outbreak, December 2014-January 2015
FDA approves a second vaccine to prevent serogroup B meningococcal disease
Don't Inject Patients with IV solutions from Wallcur
FDA Alert - updated 1/14/15
>> Read More
A new CID study raises alarms about using antibiotics for travelers’ diarrhea and the global spread of drug-resistant bacteria.
From the PresidentAntimicrobial Resistance AdvocacyIDSA Ebola GrantsMedical Scholars Program
For frail older adults living in long-term care facilities, the high-dose influenza vaccine appears to be a better option than the regular shot.
Legislation to establish a new limited population antibacterial drug approval pathway for antibacterial drugs to treat serious or life-threatening infections where there exists an unmet medical need.
A recent report from the Centers for Disease Control and Prevention (CDC) finds that the predominant circulating H3N2 influenza virus in the US has mutated, or drifted, from the corresponding vaccine strain.
In this issue:President's MessageReports from IDWeek 2014IDWeek Post Meeting Resources2014 Society Award Winners
In this issue:
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2015 Infectious Diseases Society of America